OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Dublin, Dec. 21, 2016 -- Research and Markets has announced the addition of the "Diabetic Neuropathy Drugs Price Analysis and Strategies - 2016" report to their offering.
Diabetic Neuropathy Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Diabetic Neuropathy market.
The research answers the following questions:
- What are the key drugs marketed for Diabetic Neuropathy and their clinical attributes? How are they positioned in the Global Diabetic Neuropathy market?
- What are the unit prices and annual treatment cost for Diabetic Neuropathy therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Diabetic Neuropathy drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Diabetic Neuropathy?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Diabetic Neuropathy including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Diabetic Neuropathy
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Diabetic Neuropathy market
- Diabetic Neuropathy Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Diabetic Neuropathy New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/v5fhz9/diabetic
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Endocrine and Metabolic Disorder Drugs
